Creo Medical eyes transition to full commercialisation in FY25.

Medical device company Creo Medical said on Monday that it would transition from development to full commercialisation in FY25.

CREO MEDICAL GROUP
17 February 2025 12:01:17

Source: Sharecast

Creo Medical said revenues came to £30.4m in FY24, down slightly from £30.8m a year earlier. However, it said it had delivered a 74% increase in "Creo core technology" revenues to £4.0m.

The AIM-listed group stated that actions to reduce costs in H2 had resulted in a decrease in operating costs of approximately £5.0m, with the full benefit of its cost-cutting programme set to come through in FY25.

Creo also noted that its sale of a 51% stake in its Creo Europe business to Micro-Tech, with proceeds of approximately €30.0m payable in cash received on 14 February. Following completion of the sale, the group's cash and equivalents were £31.2m.

Looking forward, Creo added that the start to the year has been "positive" and that it was trading in line with management expectations.

As of 1200 GMT, Creo Medical shares were down 7.41% at 17.50p.

Reporting by Iain Gilbert at Sharecast.com

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.